Shopping Cart
- Remove All
- Your shopping cart is currently empty
NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | 227 € | 6-8 weeks | |
25 mg | 727 € | 6-8 weeks | |
50 mg | 946 € | 6-8 weeks | |
100 mg | 1.415 € | 6-8 weeks |
Description | NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 is also an effective anti-tumor agent that displays selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 offers possibilities |
In vitro | NSC745885 (0.5-4 μM; 24 hours) enhances annexin V positive cells and reduces XIAP protein levels (0.5-2 μM; 24 or 48 hours) in a dose-dependent manner, significantly decreasing the densities of cultured SAS cells compared to untreated cells, with an IC50 of 0.85 μM after 72 hours’ treatment [1]. |
In vivo | NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) significantly reduces tumor size compared to the vehicle control and demonstrates higher safety than doxorubicin[1]. |
Molecular Weight | 266.27 |
Formula | C14H6N2O2S |
Cas No. | 4219-52-7 |
Relative Density. | 1.574 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.